Basis of Presentation and Summary of Significant Accounting Policies (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2026

Dec. 31, 2025

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Schedule of Customers Revenue or Accounts Receivable

The following table summarizes customers that accounted for 10% or more of revenue or accounts receivable:

		Revenue								Accounts Receivable
		Three Months Ended March 31,								As of March 31,				As of December 31,
		2026				2025				2026				2025
Customer A			36	%			10	%			20	%			20	%
Customer B			25	%			14	%			53	%			49	%
Customer C			18	%			*				14	%			18	%
Customer D			17	%			*				10	%			11	%
Customer E			*				62	%			*				*

*

Represents less than 10%

The following table summarizes customers that accounted for 10% or more of revenue or accounts receivable:

		Revenue								Accounts Receivable
		For the year ended December 31,								As of December 31,
		2025				2024				2025				2024
Customer A			29	%			*				*				*
Customer B			22	%			29	%			20	%			*
Customer C			13	%			16	%			18	%			*
Customer D			13	%			16	%			11	%			*
Customer E			22	%			37	%			49	%			87	%

*

Represents less than 10%

Schedule of Accounts Receivable, Net

Accounts receivable are stated net of an allowance for credit losses. The following table summarizes accounts receivable, net (in thousands):

		March 31, 2026				December 31, 2025
Gross accounts receivable		$	1,329			$	3,382
Allowance for credit losses			—				(2,129	)
Accounts receivable, net		$	1,329			$	1,253

Schedule of Disaggregated Revenue

The following table presents revenue disaggregated by major product and service lines for the three months ended March 31, 2026 and 2025:

		Three Months Ended March 31,
		2026				2025
Diagnostic drug and medical radioisotopes sales		$	1,071			$	990
Cyclotron system sales			—				1,600
Total		$	1,071			$	2,590

The following table presents revenue disaggregated by major product and service lines for the years ended December 31, 2025 and 2024:

		2025				2024
Diagnostic drug and medical radioisotopes sales		$	4,268			$	3,538
Cyclotron system sales			1,743				3
Consulting services and system support services			1				44
Total		$	6,012			$	3,585

Schedule of Estimated Useful Lives of The Assets

Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets in accordance with the following table:

Fixed asset category		Estimated useful life
Computer equipment		3 years
Computer software		3 – 5 years
Production and laboratory equipment		5 years
Specialized Technical Equipment		20 years
Cyclotron systems		20 years
Leasehold improvements		Shorter of the useful life of the leasehold improvement or the remaining term of the lease